Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer, Astellas...

    Pfizer, Astellas Pharma get USFDA nod for prostate cancer therapy Xtandi

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-17T09:15:38+05:30  |  Updated On 17 Dec 2019 9:15 AM IST

    Pfizer said Xtandi, in combination with an anti-hormone therapy, reduced the risk of cancer spreading or deaths by 61% in men with the disease, compared to placebo plus anti-hormone therapy.


    New Delhi: The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.


    The drug can now also be used to treat patients with metastatic hormone-sensitive prostate cancer, a form of prostate cancer that spreads to other parts of the body.


    More than 40,000 men in the United States are living with the disease, according to the companies.


    Pfizer said Xtandi, in combination with an anti-hormone therapy, reduced the risk of cancer spreading or deaths by 61% in men with the disease, compared to placebo plus anti-hormone therapy.


    The drug is the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer, the companies said.


    Read Also: Pfizer gets USFDA nod for Xeljanz XR Extended-Release Tablets to treat Ulcerative Colitis


    The FDA has earlier approved the drug for non-metastatic prostate cancer, a form of cancer which does not spread to other parts of the body, and metastatic castration-resistant prostate cancer, which spreads and continues to grow despite hormone therapy.


    Xtandi has been prescribed to more than 420,000 patients worldwide since it was first approved in 2012, according to the companies.


    Read Also: Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production

    AstellasPfizerpharmapharma companypharma newsprostate cancerUSFDAXtandi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok